title: Analysis of endovascular graft treatment for aortoiliac occlusive disease: what is its role based on midterm results?
abstract: OBJECTIVE
  To analyze the authors' midterm results (up to 4 years) using endovascular grafts to treat aortoiliac occlusive disease in patients with limb-threatening ischemia.
  
  
  BACKGROUND
  Endovascular grafts are being used to manage some aortoiliac lesions formerly treated by aortofemoral or extraanatomic bypass grafts. However, widespread acceptance of these new grafts depends on their late patency and clinical utility.
  
  
  METHODS
  Between January 1993 and December 1997, 52 patients with aortoiliac occlusive disease were treated with endovascular grafts. The primary indication for treatment was gangrene or ulceration in 42 patients (81%) and rest pain in 10 patients (19%). Sixteen patients had symptomatic contralateral limbs that were also treated, and 27 (52%) patients required a synchronous infrainguinal bypass. Results up to 4 years were evaluated by life table analysis.
  
  
  RESULTS
  Forty-six (88%) of the patients had complete follow-up of 3 to 57 months (median 22 months). Six patients were lost to follow-up at a mean of 20 months after surgery. The 4-year primary and secondary patency rates for the endovascular grafts were 66.1% and 72.3% respectively. Six patients required a major amputation, and the limb salvage rate was 88.7%. Four-year patient survival was 37%, with 23 patients dying during this follow-up period.
  
  
  CONCLUSIONS
  Endovascular grafts can often be used when conventional procedures are contraindicated or technically impractical. These grafts are a valuable alternative to extraanatomic and aortofemoral bypasses in high-risk patients with aortoiliac occlusive disease and critical ischemia.
authors.affiliation: Department of Surgery, Montefiore Medical Center, Bronx, New York 10467, USA.
authors.forename: R A
authors.initials: RA
authors.lastname: Wain
authors.forename: F J
authors.initials: FJ
authors.lastname: Veith
authors.forename: M L
authors.initials: ML
authors.lastname: Marin
authors.forename: T
authors.initials: T
authors.lastname: Ohki
authors.forename: W D
authors.initials: WD
authors.lastname: Suggs
authors.forename: J
authors.initials: J
authors.lastname: Cynamon
authors.forename: J
authors.initials: J
authors.lastname: Goldsmith
authors.forename: L A
authors.initials: LA
authors.lastname: Sanchez
mesh_terms: D000368:Aged; D001012:Aorta, Abdominal / Q000601:surgery*; D001157:Arterial Occlusive Diseases / Q000601:surgery*; D001807:Blood Vessel Prosthesis; D019917:Blood Vessel Prosthesis Implantation / Q000379:methods; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007083:Iliac Artery / Q000601:surgery*; D008297:Male; D011138:Polytetrafluoroethylene; D014654:Vascular Patency
chemical_list: D011138:Polytetrafluoroethylene